FRANKFURT, Oct 10 (Reuters) - Merck KGaA's Rebif multiple-sclerosis drug is not superior to rival Teva's Copaxone, a study obtained by Reuters on Wednesday showed. "The number of events (relapses) was ...
An estimated 2.5 million people suffer from multiple sclerosis (MS) worldwide—less than 0.04% of the global population. However, the epidemiology of the disease appears to be undergoing dramatic ...
Verywell Health on MSN
DMT treatment options for multiple sclerosis
Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...
A retrospective study comparing outcomes of relapsing-remitting multiple sclerosis patients treated either with COPAXONE or high-dose interferon beta-1a demonstrated that patients continuously treated ...
“We believe that a head-to-head trial is necessary to provide scientific data that can be used to compare different therapeutic options,” said Serono’s chief medical officer, Paul Lammers. “We expect ...
EXTON, Pa., Nov. 2, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US. ChartTrends®: ...
Merck, a leading science and technology company, today announced that data for approved and investigational multiple sclerosis (MS) treatments, MAVENCLAD ® (Cladribine Tablets) and Rebif ® (interferon ...
Rebif is used to treat multiple sclerosis and clinically isolated syndrome. It can interact with certain monoclonal antibodies like alemtuzumab and ozanimod, increasing the risk of infection. Drinking ...
Multiple sclerosis—so named because the disease results in multiple scars (or scleroses) on the myelin sheath, which surrounds the body's neurons—affects the body's central nervous system. Symptoms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback